| 1 |
NCT03408041 |
Completed |
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters |
|
- Other: Medical file data extraction
|
Observational |
|
- Murielle Surquin
- Brugmann University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Age
- Sex
- Ethnic origin
- (and 2 more...)
|
129 |
All |
Child, Adult, Senior |
NCT03408041 |
CHUB-parameters Alzheimer |
|
May 1, 2016 |
October 1, 2017 |
October 1, 2017 |
January 23, 2018 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium
|
| 2 |
NCT02022943 |
Recruiting |
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies |
- Alzheimer's Disease
- Dementia
|
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Other
|
- Number of individuals enrolled into Alzheimer's prevention studies
- Number of individuals referred to Alzheimer's prevention research studies / sites
|
500000 |
All |
18 Years to 110 Years (Adult, Senior) |
NCT02022943 |
APR |
APR |
May 2012 |
January 2030 |
January 2030 |
December 30, 2013 |
October 23, 2017 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States
|
| 3 |
NCT03340571 |
Recruiting |
Blood Biomarker of Alzheimer's Disease (AD) |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological marker of Alzheimer's disease
|
60 |
All |
50 Years and older (Adult, Senior) |
NCT03340571 |
Pro00085997 |
|
March 12, 2018 |
August 2018 |
August 2018 |
November 13, 2017 |
March 14, 2018 |
|
- Duke University
Durham, North Carolina, United States
|
| 4 |
NCT01624389 |
Unknown † |
Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study |
|
|
Interventional |
Not Applicable |
- Chang Gung Memorial Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Rate of conversion from NC, EMCI, LMCI to AD.
|
200 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01624389 |
101-1074A1 |
Alzheimer's |
January 2012 |
January 2015 |
January 2015 |
June 20, 2012 |
June 20, 2012 |
|
- Tzu-Chen-Yen
Taoyuan, Taiwan
|
| 5 |
NCT02986932 |
Recruiting |
Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in contrast enhancement (intensity) following BBB disruption
- Change in amyloid uptake
- Adverse events
- (and 5 more...)
|
6 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02986932 |
AL001 |
BBB-Alzheimers |
December 2016 |
December 2017 |
December 2017 |
December 8, 2016 |
March 28, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
| 6 |
NCT03472183 |
Not yet recruiting
New |
Exploration of the Enteric Nervous System in Alzheimer Disease |
|
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease
- Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
|
30 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03472183 |
RC17_0252 |
SYNEMA |
March 25, 2018 |
November 25, 2020 |
November 25, 2020 |
March 21, 2018 |
March 21, 2018 |
|
|
| 7 |
NCT02349191 |
Not yet recruiting |
Omental Transposition Surgery for Mild Alzheimer's Disease |
|
- Procedure: Omental transposition for mild Alzheimers disease
|
Interventional |
Not Applicable |
- Bariatric Medicine Institute, Salt Lake City, UT
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.
- Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.
- Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months
- (and 6 more...)
|
25 |
All |
65 Years to 85 Years (Adult, Senior) |
NCT02349191 |
Cottam - 1 |
|
March 2016 |
April 2017 |
May 2019 |
January 28, 2015 |
March 22, 2016 |
|
|
| 8 |
NCT02672306 |
Not yet recruiting |
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease |
|
- Biological: UCMSCs
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
- South China Research Center for Stem Cell and Regenerative Medicine
- Third Affiliated Hospital, Sun Yat-Sen University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Guangzhou Psychiatric Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
40 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02672306 |
UCMSC-1 |
SEESUPAD |
May 2016 |
October 2018 |
October 2019 |
February 3, 2016 |
February 3, 2016 |
|
|
| 9 |
NCT01692977 |
Completed |
What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? |
|
- Other: neuropsychological assessment
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Analyze nature and frequency of elements of the " art, memory and life " garden used as landmarks by Alzheimer's disease patients
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.
|
77 |
All |
65 Years to 90 Years (Adult, Senior) |
NCT01692977 |
2011-A00993-38 |
JAZ-TOP |
August 2012 |
October 2014 |
October 2014 |
September 26, 2012 |
July 30, 2015 |
|
- University Hospital of Nancy , Saint Julien Hospital, France
Nancy, France
|
| 10 |
NCT02854033 |
Recruiting |
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol |
- Mild Cognitive Impairment (MCI)
- Alzheimer's Disease (AD)
|
|
Observational |
|
- University of Southern California
- Northern California Institute of Research and Education
- National Institute on Aging (NIA)
- Alzheimer's Therapeutic Research Institute
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
- Rate of change in cognition as measured by the Logical Memory Test I and II
- Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)
- (and 12 more...)
|
2000 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT02854033 |
ATRI-001
U01AG024904 |
ADNI3 |
October 2016 |
October 2021 |
October 2021 |
August 3, 2016 |
February 12, 2018 |
|
- University of Alabama, Birmingham
Birmingham, Alabama, United States - Banner Alzheimer's Institute
Phoenix, Arizona, United States - Barrow Neurological Institute
Phoenix, Arizona, United States - (and 56 more...)
|
| 11 |
NCT03373604 |
Enrolling by invitation |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-MK-6240
- Procedure: Lumbar Puncture (optional)
|
Interventional |
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-MK-6240 binding (standardized uptake value ratio)
- Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.
|
175 |
All |
50 Years to 100 Years (Adult, Senior) |
NCT03373604 |
AAAR4352
K23AG052633-02 |
|
December 11, 2017 |
August 20, 2021 |
August 20, 2021 |
December 14, 2017 |
January 10, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 12 |
NCT02565511 |
Recruiting |
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
|
Interventional |
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Banner Alzheimer's Institute
- National Institute on Aging (NIA)
- (and 3 more...)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 7 more...)
|
1340 |
All |
60 Years to 75 Years (Adult, Senior) |
NCT02565511 |
CAPI015A2201J
2015-002715-15
1UF1AG046150-01 |
Generation S1 |
November 30, 2015 |
August 30, 2024 |
September 2, 2024 |
October 1, 2015 |
April 18, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Banner Sun City Research Institute
Sun City, Arizona, United States - (and 73 more...)
|
| 13 |
NCT02208193 |
Unknown † |
Alzheimer's Disease, Art and Garden |
|
- Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Comparaison of the number of language acts in each category between AD and controls subjects
- Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),
- Scores obtained with the " MemoArtZ " tool (MAZ) to evaluate the memorization of artistic elements of the garden,
- (and 3 more...)
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02208193 |
2014-A00139-38 |
JAZ ART |
July 2014 |
October 2016 |
September 2017 |
August 4, 2014 |
July 30, 2015 |
|
|
| 14 |
NCT00987090 |
Unknown † |
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) |
|
- Biological: Clinic and neuropsychologic evaluation
- Radiation: MRI
- Procedure: PET
- (and 2 more...)
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.
- to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.
|
240 |
All |
45 Years to 90 Years (Adult, Senior) |
NCT00987090 |
2008/24
2008-A01213-52 |
|
October 2009 |
September 2016 |
|
September 30, 2009 |
October 23, 2015 |
|
- Assistance Publique - Hôpitaux de Marseille
Marseille, France
|
| 15 |
NCT03255720 |
Not yet recruiting |
Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease.
|
40 |
All |
60 Years to 80 Years (Adult, Senior) |
NCT03255720 |
diffusion tensor imaging |
|
September 29, 2017 |
December 1, 2022 |
December 31, 2022 |
August 21, 2017 |
September 26, 2017 |
|
|
| 16 |
NCT02703636 |
Recruiting |
Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease |
- Mild to Moderate Alzheimer's Disease
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE)
- Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs).
- Change from baseline to Week 8 in Mini-Mental State Examination (MMSE) total score.
- (and 5 more...)
|
120 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02703636 |
CENA713DJP02 |
ENA1stepswitch |
May 10, 2016 |
April 24, 2018 |
April 24, 2018 |
March 9, 2016 |
June 21, 2017 |
|
- Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Aizuwakamatsu, Fukushima, Japan - (and 17 more...)
|
| 17 |
NCT00412048 |
Withdrawn |
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease |
|
- Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects
- Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease
|
0 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT00412048 |
3659 |
|
April 2012 |
February 2018 |
February 2018 |
December 15, 2006 |
November 14, 2012 |
|
|
| 18 |
NCT03132272 |
Recruiting |
Immunoadsorption for Treatment of Alzheimer's Disease |
|
- Device: Immunoadsorption with Globaffin
|
Interventional |
Not Applicable |
- University Medicine Greifswald
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI
- Cognition (changes/improvement/impairment)
- Vascular effects
- (and 2 more...)
|
15 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03132272 |
201503IMAD
CIV-16-02-014668 |
IMAD |
June 2016 |
July 2018 |
July 2018 |
April 27, 2017 |
April 27, 2017 |
|
- University Medicine Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany
|
| 19 |
NCT03055741 |
Recruiting |
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil |
- Mild-moderate Alzheimer's Disease
|
- Drug: Donepezil
- Drug: DHP1401
- Drug: Placebo
|
Interventional |
Phase 2 |
- Daehwa Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)
- Clinical Dementia Rating Sum of Box Korean version(CDR-SB)
- Neuropsychiatric Inventory-Q Korean version(NPI-Q)
- (and 3 more...)
|
180 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03055741 |
1401CS-2 |
|
December 28, 2016 |
September 2018 |
September 2018 |
February 16, 2017 |
December 4, 2017 |
|
- The Catholic University of Korea, Bucheon, ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, Korea, Republic of - Myongji Hospital
Goyang-si, Gyeonggi-do, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of - (and 8 more...)
|
| 20 |
NCT01928420 |
Completed |
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease |
- Alzheimer's Disease
- Dementia
|
- Drug: Drug: NIC5-15
- Drug: Placebo
|
Interventional |
Phase 2 |
- Humanetics Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- James J. Peters Veterans Affairs Medical Center
|
Industry / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
30 |
All |
40 Years to 95 Years (Adult, Senior) |
NCT01928420 |
R21AT003302-01A1
MHBB-009-06S |
|
April 2007 |
June 2014 |
June 2014 |
August 26, 2013 |
October 17, 2016 |
|
- James J Peters Veterans Affairs Medical Center
Bronx, New York, United States
|
| 21 |
NCT02769234 |
Enrolling by invitation |
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD) |
|
- Procedure: ERP/EEG test
- Procedure: Psychometric testing
|
Observational |
|
- Neuronetrix, Inc.
- Boston Center for Memory
- The Memory Clinic of Vermont
- Premiere Research Institute
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.
- Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.
- Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.
|
75 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02769234 |
SRP-1782 |
|
May 2016 |
June 2017 |
July 2017 |
May 11, 2016 |
May 30, 2017 |
|
- Premiere Research Institute
West Palm Beach, Florida, United States - Boston Center for Memory
Brookline, Massachusetts, United States - The Memory Clinic
Bennington, Vermont, United States
|
| 22 |
NCT02702817 |
Completed |
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia |
- Alzheimer Disease
- Cognitive Decline Due to Alzheimer Disease
- Mild Cognitive Impairment Due to Alzheimer Disease
|
- Drug: Naproxen
- Drug: Placebo
|
Interventional |
Phase 2 |
- Douglas Mental Health University Institute
- McGill University
- Johns Hopkins University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease
- frequency and severity of treatment-emergent adverse events
- trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status
- (and 3 more...)
|
200 |
All |
55 Years and older (Adult, Senior) |
NCT02702817 |
INTREPAD |
|
August 1, 2012 |
March 31, 2017 |
July 15, 2017 |
March 9, 2016 |
August 1, 2017 |
|
- Douglas Hospital Research Centre
Montreal, Quebec, Canada
|
| 23 |
NCT02253043 |
Recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease |
|
- Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
|
Interventional |
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
- Clinical Dementia Rating Scale
|
10 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02253043 |
PINS-002 |
|
May 2014 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - 301 Hospatl
Beijing, Beijing, China
|
| 24 |
NCT00973518 |
Completed |
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects
- Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test)
- (and 2 more...)
|
160 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT00973518 |
ADD 09-02 |
|
September 2009 |
June 2010 |
June 2010 |
September 9, 2009 |
August 13, 2010 |
|
- Rush Alzheimer's Disease Center
Chicago, Illinois, United States - Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois, United States
|
| 25 |
NCT02158910 |
Completed |
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients |
|
|
Observational |
|
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
|
2231 |
All |
Child, Adult, Senior |
NCT02158910 |
ART-M082-601 |
AID |
March 2015 |
June 2016 |
June 2016 |
June 9, 2014 |
March 7, 2017 |
|
- Busan, Korea, Republic of
- Chungcheongbuk-do, Korea, Republic of
- Chungcheongnam-do, Korea, Republic of
- (and 10 more...)
|
| 26 |
NCT01504958 |
Completed
Has Results |
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients |
|
- Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
- Behavioral: NICE Cognitive Training
|
Interventional |
Not Applicable |
- Beth Israel Deaconess Medical Center
- Neuronix Ltd
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
- Clinical Global Impression of Change (CGIC)
- Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)
|
22 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01504958 |
2010P000325 |
|
December 2010 |
May 2015 |
May 2015 |
January 6, 2012 |
July 2, 2017 |
June 5, 2017 |
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 27 |
NCT01466088 |
Completed |
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) |
|
- Drug: Donepezil
- Drug: AZD3480
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)
- Change from baseline in the Clinician Interview-Based Impression of Change plus carer interview [CIBIC-(+)]
- Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
- (and 3 more...)
|
386 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01466088 |
TC-1734-226-CRD-006 |
|
October 2011 |
May 2014 |
May 2014 |
November 7, 2011 |
June 3, 2015 |
|
- Banner Alzheimer Institute
Phoenix, Arizona, United States - Meridien Research
Brooksville, Florida, United States - MD Clinical
Hallandale Beach, Florida, United States - (and 30 more...)
|
| 28 |
NCT01883648 |
Terminated |
Study to Evaluate Coconut Oil for Alzheimer's Disease |
|
- Drug: Coconut Oil Beverage
- Other: Placebo Beverage
|
Interventional |
Phase 2
Phase 3 |
- University of South Florida
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale
- (and 4 more...)
|
21 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01883648 |
Byrd AD-001 |
|
June 2013 |
February 1, 2017 |
February 1, 2017 |
June 21, 2013 |
April 28, 2017 |
|
- USF Health Byrd Alzheimer's Institute
Tampa, Florida, United States
|
| 29 |
NCT02959489 |
Recruiting |
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
- Alzheimer Disease
- Amyloid Beta-Peptides
- Risk Assessment
- (and 3 more...)
|
- Behavioral: Alzheimer's Disease Risk Disclosure
- Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- University of Pennsylvania
- University of Michigan
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure
- Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.
- Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.
|
270 |
All |
65 Years to 80 Years (Adult, Senior) |
NCT02959489 |
RF1AG047866
1RF1AG047866-01A1 |
REVEAL-SCAN |
November 2016 |
July 2019 |
July 2019 |
November 9, 2016 |
December 20, 2016 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States - Duke University
Durham, North Carolina, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 30 |
NCT03090854 |
Not yet recruiting |
Cholinergic Markers Alzheimer's Disease |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Neuropsychological test (ADASCog)
- Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
- Difference of CSF Ach AND AChE activity between responder and non responder groups
- Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
|
100 |
All |
50 Years and older (Adult, Senior) |
NCT03090854 |
K160402
2016-AO1639-42 |
CHOLINE |
September 1, 2017 |
September 1, 2019 |
September 1, 2019 |
March 27, 2017 |
August 29, 2017 |
|
- Centre Mémoire de Ressources et de Recherche Paris Nord
Paris, France
|
| 31 |
NCT02947893 |
Recruiting |
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease |
|
- Drug: Placebo Capsule(s) Once a Day by Mouth
- Drug: Nilotinib Capsule(s) Once a Day by Mouth
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values
- Effects of Nilotinib treatment on measurement of Nilotinib in the CSF
|
42 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02947893 |
2016-0315 |
AD |
January 2017 |
February 2019 |
December 2019 |
October 28, 2016 |
February 20, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
| 32 |
NCT01409915 |
Active, not recruiting |
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease |
|
- Drug: Sagramostim
- Drug: Saline -- placebo comparator
|
Interventional |
Phase 2 |
- University of Colorado, Denver
- The Dana Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed
- Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects
|
40 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT01409915 |
12-1273 |
|
March 2011 |
November 2018 |
November 2018 |
August 4, 2011 |
January 18, 2018 |
|
- University of Colorado Denver, Anschutz Medical Campus
Aurora, Colorado, United States
|
| 33 |
NCT01926249 |
Active, not recruiting |
A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders |
- Alzheimer's Disease (AD) and Related Disorders
|
|
Observational |
|
- University Hospital, Bordeaux
- Fondation Plan Alzheimer
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)
- Mortality
- Loss of autonomy based on functional activity assessment
- (and 6 more...)
|
2300 |
All |
18 Years and older (Adult, Senior) |
NCT01926249 |
CHUBX 2010/47 |
MEMENTO |
April 2011 |
June 2019 |
June 2019 |
August 20, 2013 |
April 6, 2017 |
|
- CHU d'Amiens
Amiens, France - CHU d'Angers
Angers, France - CHU de Besançon
Besancon, France - (and 26 more...)
|
| 34 |
NCT01850238 |
Completed |
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease |
|
- Biological: AADvac1
- Other: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
|
30 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01850238 |
AXON CO 18700
2012-003916-29 |
|
May 2013 |
March 2015 |
March 2015 |
May 9, 2013 |
October 12, 2015 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria
|
| 35 |
NCT02279511 |
Completed |
ATP in Alzheimer Disease |
|
- Drug: ADENOSINE TRIPHOSPHATE
- Drug: PLACEBO
|
Interventional |
Phase 2 |
- Sara Varea
- Fundacion Clinic per a la Recerca Biomédica
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)
- Changes in Cogstate results
- Changes in test Mini-Mental State Examination
- (and 3 more...)
|
20 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02279511 |
ECA4A |
|
December 2014 |
February 2016 |
February 2016 |
October 31, 2014 |
March 29, 2017 |
|
- Fundació ACE
Barcelona, Spain - Hospital Sanitas CIMA
Barcelona, Spain
|
| 36 |
NCT00876863 |
Active, not recruiting |
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease |
|
- Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF
- Procedure: Placebo Surgery
|
Interventional |
Phase 2 |
- Sangamo Therapeutics
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
- Neuropsychological Test Battery
- Mini-Mental State Examination (MMSE)
- (and 2 more...)
|
50 |
All |
55 Years to 80 Years (Adult, Senior) |
NCT00876863 |
CERE-110-03
NIH Grant 1R01AG030048-01A1 |
|
September 2009 |
December 2019 |
March 2020 |
April 7, 2009 |
January 10, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California, Los Angeles
Los Angeles, California, United States - University of California, San Diego
San Diego, California, United States - (and 7 more...)
|
| 37 |
NCT01867372 |
Terminated |
Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes |
|
|
Observational |
|
- National Institute on Aging (NIA)
- Johns Hopkins University
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
|
- Accelerated preclinical changes in brain structure and function in specific regions will predict which individuals develop cognitive impairment and Alzheimer s disease
- Changes in brain structure are predictors of cognitive decline and impairment though neuroimaging assessments
|
213 |
All |
20 Years and older (Adult, Senior) |
NCT01867372 |
999903328
03-AG-N328 |
|
March 10, 2003 |
September 22, 2014 |
September 22, 2014 |
June 4, 2013 |
April 17, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Kennedy Krieger Institute
Baltimore, Maryland, United States - National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States
|
| 38 |
NCT03136679 |
Recruiting |
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease |
- Mild Cognitive Impairment
- Alzheimer Disease
|
|
Observational |
|
- Baylor Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.
|
220 |
All |
40 Years and older (Adult, Senior) |
NCT03136679 |
017-039 |
BVB |
March 22, 2017 |
April 30, 2019 |
December 31, 2019 |
May 2, 2017 |
May 4, 2017 |
|
- Baylor AT&T Memory Center
Dallas, Texas, United States
|
| 39 |
NCT02899091 |
Not yet recruiting |
Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease |
|
- Biological: CB-AC-02
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Adverse Events
- Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score
- Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score
- (and 11 more...)
|
24 |
All |
50 Years and older (Adult, Senior) |
NCT02899091 |
CHA-PAD-101 |
|
September 2016 |
March 2018 |
June 2018 |
September 14, 2016 |
September 14, 2016 |
|
- Bundang Medical Center
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
| 40 |
NCT02377206 |
Unknown † |
Neuroinflammation and Cognitive Decline in Alzheimer Disease |
|
- Other: ADAS-Cog evaluation
|
Interventional |
Phase 1 |
- University Hospital, Tours
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from baseline in ADAS-Cog score
- Quantification of neuroinflammation by [18F]DPA-714 PET imaging
|
45 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT02377206 |
PRTS13-CH / NICAD |
NICAD |
March 2015 |
March 2017 |
March 2017 |
March 3, 2015 |
June 23, 2015 |
|
- University hospital of Caen
Caen, France - university hospital of Nantes
Nantes, France - University Hospital of Rennes
Rennes, France - University Hospital of Tours
Tours, France
|
| 41 |
NCT02031198 |
Completed |
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
- Patient cognition
|
25 |
All |
50 Years to 86 Years (Adult, Senior) |
NCT02031198 |
AC-AD-002
2013-004499-36 |
FUNDAMANT |
January 2014 |
August 2016 |
December 2016 |
January 9, 2014 |
March 17, 2017 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria - Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders
Wien, Austria
|
| 42 |
NCT02769000 |
Recruiting |
Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's |
|
- Radiation: 10 GY in 5 daily fractions
- Radiation: 20 GY in 10 daily fractions
|
Interventional |
Not Applicable |
- Virginia Commonwealth University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate safety and toxicity/adverse events associated with delivery of low dose fractionated whole brain irradiation in subjects with early Alzheimer's dementia according to NINCDS-ADRDA Criteria.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using neurcognitive testing methods.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using psychological functioning tests.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using Quality of Life indices.
|
30 |
All |
55 Years and older (Adult, Senior) |
NCT02769000 |
HM20004955 |
|
May 2016 |
April 2019 |
April 2019 |
May 11, 2016 |
March 29, 2018 |
|
- Virginia Commonwealth University
Richmond, Virginia, United States
|
| 43 |
NCT00945672 |
Completed |
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease |
|
- Biological: PF-04360365 10 mg/kg
- Biological: PF-04360365 7.5 mg/kg
- Drug: placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)
- Brain amyloid burden
- CSF abeta
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)
|
36 |
All |
50 Years and older (Adult, Senior) |
NCT00945672 |
A9951007 |
|
August 2009 |
June 2011 |
June 2011 |
July 24, 2009 |
May 5, 2016 |
|
- Pfizer Investigational Site
Göteborg, Sweden - Pfizer Investigational Site
Malmo, Sweden - Pfizer Investigational Site
Molndal, Sweden - Pfizer Investigational Site
Stockholm, Sweden
|
| 44 |
NCT02884492 |
Active, not recruiting |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-THK- 5351
- Procedure: Lumbar Puncture (optional)
|
Interventional |
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-THK-5351 binding (standardized uptake value ratio)
- Cerebral spinal fluid (CSF) concentration of amyloid, tau, and inflammatory markers
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02884492 |
AAAQ7868
1K23AG052633-01 |
|
July 2016 |
June 2021 |
June 2021 |
August 31, 2016 |
December 13, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 45 |
NCT02501876 |
Completed |
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease |
- Alzheimer´s Disease
- Diabetes Mellitus Type 2
|
- Other: There is a retrospectiv observational study. No intervention
|
Observational |
|
- Hospital Universitari Vall d'Hebron Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- The rate of conversion to Alzheimer's disease (AD)
- The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2
|
202 |
All |
65 Years to 90 Years (Adult, Senior) |
NCT02501876 |
PR(AG)32/2015 |
DIACEA |
May 2015 |
September 2015 |
May 2016 |
July 17, 2015 |
April 12, 2017 |
|
- Vall d´Hebron University Hospital
Barcelona, Spain
|
| 46 |
NCT01023867 |
Completed |
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia |
- Alzheimer's Disease
- Dementia
|
|
Interventional |
Not Applicable |
- Samsung Medical Center
- Eisai Korea Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)
- Seoul Activities of Daily Living (S-ADL)
- Seoul-Instrumental Activities of Daily Living (S-IADL)
- Korean Neuropsychiatric Inventory (K-NPI)
|
88 |
All |
Child, Adult, Senior |
NCT01023867 |
2007-03-039 |
|
March 2007 |
June 2010 |
June 2010 |
December 2, 2009 |
January 6, 2016 |
|
- Samsung Medical Center
Seoul City, Korea, Republic of
|
| 47 |
NCT01424436 |
Completed |
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- (and 2 more...)
|
19 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT01424436 |
113043 |
|
May 19, 2010 |
December 8, 2011 |
December 8, 2011 |
August 29, 2011 |
June 14, 2017 |
|
- GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany - GSK Investigational Site
Tuebingen, Baden-Wuerttemberg, Germany - GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany - (and 4 more...)
|
| 48 |
NCT02292238 |
Recruiting |
Benfotiamine in Alzheimer's Disease: A Pilot Study |
|
|
Interventional |
Phase 2 |
- Burke Medical Research Institute
- Burke Rehabilitation Hospital
- Columbia University
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ADAS-cog as the primary clinical outcome
- Brain glucose utilization
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- (and 3 more...)
|
76 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02292238 |
BRC-451
1R01AG043679-01A1 |
Benfotiamine |
November 2014 |
November 2018 |
November 2019 |
November 17, 2014 |
January 17, 2018 |
|
- Burke
White Plains, New York, United States
|
| 49 |
NCT00357357 |
Completed |
European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients
- Validate biochemical markers relevant to Alzheimer's disease
- Assess the suitability of chosen HF0220 dose levels for future studies
|
40 |
All |
55 Years and older (Adult, Senior) |
NCT00357357 |
HF0220/003
2005-005791-32 |
|
July 2006 |
August 2008 |
August 2008 |
July 27, 2006 |
August 21, 2008 |
|
- King George Hospital
Visakhapatnam, Andh Prad, India - Manipal Hospital,
Bangalore, Karna, India - Sree Chitra Tirunal Institute for Medical Sciences and Technology
Thiruvananthapuram, Kerala, India - (and 7 more...)
|
| 50 |
NCT02195596 |
Unknown † |
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study. |
|
- Other: High intensity aerobic exercise+strength
- Other: Low intensity aerobic exercise+strength
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
- Global cognitive performance
|
80 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02195596 |
2011111100 |
EFA-P |
April 2013 |
January 2015 |
December 2015 |
July 21, 2014 |
July 21, 2014 |
|
- Galdakao Hospital/Galdakao C.S.
Galdakao, Bilbao, Spain - Basauri C.S.
Basauri, Bizkaia, Spain - Hospital Universitario de Basurto
Bilbao, Bizkaia, Spain
|
Create an RSS feed from your search for:
Download the search results for: